Originals and Papers Central obesity but not generalised obesity (body mass index) predicts high prevalence of fatty liver (NAFlD), in recently detected untreated, IGT and type 2 diabetes Indian subjectsonmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA Oebmalya SanyaP, Pradip Mukhopadhyay2, Kaushik Pandit", Satinath Mukhopadhyay4, Subhankar Chowdhury" . Recently detected 1521GTand 158 type 2 diabetes patients aged between 30 and 69 years, never treated with any antidiabetic drug, lipid lowering agent, angiotension converting enzyme (ACE) inhibitor and/or angiotensin receptor blocker (ARB) were evaluated. One hundred and sixty asymptomatic, willing, healthy, normoglycaemic spouse or unrelated attendants accompanying the patients were also selected. History of significant alcohol intake or hepatotoxic drugs and positive serologic findings for hepatitis Band C viruses were excluded. The prevalence of fatty liver was 64% in type 2 OM,52% in impaired glucose tolerance (IGT) and 20% in normal glucose tolerance (NGT) subjects. Subjects with fatty liver had significantly higher body mass index (BMI),waist, waist hip ratio, waist to height ratio, triglyceride, fasting insulin, insulin resistance (HOMA-IR),along with significantly lower HOL-Cand quantitative insulin-sensitivity check index (QUICKI)compared to those without fatty liver. Similar findings were noted in subjects with fatty liver in the subgroups of NGT,IGTand diabetes as well, for the above mentioned parameters. There was no significant difference in total cholesterol, LOL-C between subjects with or without fatty liver. However, analysis by the multivariate regression technique revealed that QUICKI(but not HOMA-IR),waist circumference and waist to height ratio had a significant association (p<0.01 for all groups and for all these three parameters except in the NGTgroup for waist to height ratio p<0.05) with development of fatty liver. BMI on the other hand was not significantly associated With the fatty liver in the multivariate regression (p=0.067).RQPONMLKJIHGFEDCBA [J Indian Med Assoc vutsrqponmlkjihgfedcbaZYXWVU 2009; 107: 755-8] Key words: Fatty liver, NAFLD, anthropometric measures, obesity, central obesity, BMI. Dtty liver is considered to occur commonly in type 2 r diabetes mellitus, with estimates of prevalence ranging from 21 to 78%,·2. But there are very few studies offatty liver in subjects with prediabetes. Obesity and insulin resistance are considered to increase the risk of development of fatty liver':', and both of these are also characteristic of type 2 DM and prediabetes. Fatty liver can lead to steatohepatitis and progress to end-stage liver disease but clinical symptoms of fatty liver are often nonspecific or silent'. Nevertheless Department of Eridocrinology, IPGME&R and SSKM Hospital, Kolkata 700020 lMD, DM (Endocrinol), Senior Resident of Endocrinology, KPC Medical College, Kolkata 700032 2MD, DM (Endocrinol), Assistant Professor 3MD, DNB, DM (Endocrinol), Research Scientist 4MD, DM (Endocrinol), Professor 'MD, DM (Endocrinol), MRCP, Professor and Head of the Department Accepted October 21, 2009 fatty liver is not benign, even for those in whom it is non- . progressive. It can increase severity of hepatic insulin resistance in type 2 DM. Ryysy et al s observed that hepatic fat content in patients with type 2 DM predicted the amount of daily insulin needed to maintain glycaemic control. Also, among non-obese men without type 2 DM, fatty liver was found to correlate with hepatic insulin resistance independently of obesity and intra-abdominal adiposity", The objective of this study was to assess the prevalence offatty liver (NAFLD) in NGT, recently detected untreated IGT and type 2 diabetes, and to compare the various anthropometric parameters, in patients with or without fatty liver. MATERIAL AND METHOD One hundred fifty-eight consecutive patients with recently diagnosed type 2 diabetes between the age groups 30 and 69 years and 152 consecutive patients of similar age group with recently diagnosed IGT who were never treated with any antihyperglycaemic agents, lipid lowering 755